Vilon — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Vilon

Also known as: KE peptide, Lys-Glu, KE dipeptide

Short peptide bioregulator / dipeptide (Lys-Glu)

Research chemicalLast updated: October 19, 2026Based on 12 peer-reviewed studies

What it is

Vilon is a synthetic dipeptide used in the longevity community for immune modulation and anti-aging effects. Research suggests it works by influencing gene expression in immune and skin cells to slow aging processes. No FDA-approved use; primarily studied in Russian longevity research with limited independent replication.

The scientific side

Vilon (Lys-Glu, KE dipeptide) is a synthetic dipeptide bioregulator originally characterized by Prof. Khavinson and described as having immunomodulatory, oncostatic, and geroprotective effects. According to molecular modeling data, the KE peptide can interact with specific dsDNA sequences (GCGG in classical B-form dsDNA and GGGC in curved dsDNA nucleosome), with these sequences found in the promoters of the SIRT1, PARP1, and PARP2 genes, suggesting a mechanism of direct gene expression regulation (PMID 37042594; PMID 37782636). Vilon has been shown to modulate chromatin structure, inducing deheterochromatinization of facultative heterochromatin in lymphocytes from aged individuals, and activating synthetic processes of ribosomal genes. It regulates expression of genes involved in aging (IGF1, FOXO1, TERT, TNKS2, NFκB) in human mesenchymal stem cells at nanomolar concentrations, and modulates SIRT1, PARP1, and PARP2 gene expression and protein synthesis during MSC aging. It increases mitochondrial staining and decreases ribosomal protein L7A expression in thymic cells, and increases collagen type I and sirtuin-6 expression in skin fibroblasts. In the immune system, Vilon and its analogues affect CD5, CD4+, and CD8+ T-cell differentiation in thymic cell cultures. In monocyte/macrophage cell lines, Vilon modulates inflammatory and proliferative processes, including inhibition of TNF and IL-6 cytokine production and reduction of cell adhesion to activated endothelial cells.

Class: Short peptide bioregulator / dipeptide (Lys-Glu)

Administration & storage

Cautions
No human pharmacokinetic data are reported in the reviewed abstracts for Vilon; all mechanistic studies identified were conducted in vitro.,No specific safety, tolerability, or adverse event data for Vilon are reported in the reviewed abstracts — safety profile in humans is not established from this literature.,Sterile technique is essential for any injectable peptide preparation to prevent contamination.,Regulatory status of Vilon for human use is not stated in the reviewed literature; use outside of approved clinical or research settings may carry unknown risks.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification